| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fan Y et al. | Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. | 2016 | J. Biotechnol. | pmid:27173582 |
| Fan Y et al. | Process optimization with alternative carbon sources and modulation of secondary metabolism for enhanced ansamitocin P-3 production in Actinosynnema pretiosum. | 2014 | J. Biotechnol. | pmid:25456055 |
| Floss HG | Combinatorial biosynthesis--potential and problems. | 2006 | J. Biotechnol. | pmid:16414140 |
| Sandra K et al. | Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27160547 |
| Krop IE et al. | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. | 2015 | J. Clin. Oncol. | pmid:25713436 |
| Hurvitz SA et al. | Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. | 2013 | J. Clin. Oncol. | pmid:23382472 |
| Harbeck N et al. | De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. | 2017 | J. Clin. Oncol. | pmid:28682681 |
| Miller KD et al. | Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. | 2014 | J. Clin. Oncol. | pmid:24733796 |
| Giordano SH et al. | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. | 2014 | J. Clin. Oncol. | pmid:24799465 |
| Mahtani RL and Vogel CL | When Can a Salvage Therapy (T-DM1) Take the Lead? | 2016 | J. Clin. Oncol. | pmid:27432926 |
| Moore KN et al. | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. | 2017 | J. Clin. Oncol. | pmid:28029313 |
| Galsky MD et al. | Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. | 2008 | J. Clin. Oncol. | pmid:18362364 |
| Dzimitrowicz H et al. | T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. | 2016 | J. Clin. Oncol. | pmid:27298406 |
| Tolcher AW et al. | Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. | 2003 | J. Clin. Oncol. | pmid:12525512 |
| Isakoff SJ and Baselga J | Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. | 2011 | J. Clin. Oncol. | pmid:21172881 |
| Burris HA et al. | Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. | 2011 | J. Clin. Oncol. | pmid:21172893 |
| Diéras V et al. | Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. | 2014 | J. Clin. Oncol. | pmid:25024070 |
| Force J et al. | Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine. | 2016 | J. Clin. Oncol. | pmid:24778392 |
| Krop IE et al. | Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. | 2010 | J. Clin. Oncol. | pmid:20421541 |
| Younes A et al. | Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. | 2012 | J. Clin. Oncol. | pmid:22753910 |
| Krop IE et al. | A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. | 2012 | J. Clin. Oncol. | pmid:22649126 |
| Perez EA et al. | Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | 2017 | J. Clin. Oncol. | pmid:28056202 |
| Hassan R et al. | Mesothelin Immunotherapy for Cancer: Ready for Prime Time? | 2016 | J. Clin. Oncol. | pmid:27863199 |
| La Monica S et al. | Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. | 2017 | J. Exp. Clin. Cancer Res. | pmid:29202823 |
| Feng L et al. | Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer. | 2016 | J. Exp. Clin. Cancer Res. | pmid:27102688 |
| Yue W et al. | Induction of apoptosis in hormone refractory breast cancer: horizontal modulation is superior to vertical. | 2013 | J. Exp. Ther. Oncol. | pmid:24416991 |
| Tanida S et al. | Ansamitocin-induced synchrony in Tetrahymena pyriformis. | 1980 | J. Gen. Microbiol. | pmid:6777454 |
| Dillon RL et al. | Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance. | 2016 | J. Immunother. | pmid:26938945 |
| Ng D et al. | Constitutive overexpression of asm2 and asm39 increases AP-3 production in the actinomycete Actinosynnema pretiosum. | 2009 | J. Ind. Microbiol. Biotechnol. | pmid:19609582 |
| Gao Y et al. | Enhancement of ansamitocin P-3 production in Actinosynnema pretiosum by a synergistic effect of glycerol and glucose. | 2014 | J. Ind. Microbiol. Biotechnol. | pmid:24174216 |
| Kupchan SM et al. | Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids. | 1978 | J. Med. Chem. | pmid:563462 |
| Zhao RY et al. | Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. | 2011 | J. Med. Chem. | pmid:21517041 |
| Pillow TH et al. | Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. | 2014 | J. Med. Chem. | pmid:25191794 |
| Lambert JM and Chari RV | Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. | 2014 | J. Med. Chem. | pmid:24967516 |
| Widdison WC et al. | Semisynthetic maytansine analogues for the targeted treatment of cancer. | 2006 | J. Med. Chem. | pmid:16821799 |
| Sakai K et al. | Antitumor principles in mosses: the first isolation and identification of maytansinoids, including a novel 15-methoxyansamitocin P-3. | 1988 Sep-Oct | J. Nat. Prod. | pmid:3204376 |
| Novelo M et al. | Cytotoxic constituents from Hyptis verticillata. | 1993 | J. Nat. Prod. | pmid:8277312 |
| Perdue RE | KB cell culture I. Role in discovery of antitumor agents from higher plants. | 1982 Jul-Aug | J. Nat. Prod. | pmid:7130986 |
| Kusari S et al. | Endophytes are hidden producers of maytansine in Putterlickia roots. | 2014 | J. Nat. Prod. | pmid:25478947 |
| Snipes CE et al. | The ansacarbamitocins: polar ansamitocin derivatives. | 2007 | J. Nat. Prod. | pmid:17892263 |
| Tan GT et al. | Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991 Jan-Feb | J. Nat. Prod. | pmid:1710653 |
| Kuo YH et al. | Antitumor agents, 112. Emarginatine B, a novel potent cytotoxic sesquiterpene pyridine alkaloid from Maytenus emarginata. | 1990 Mar-Apr | J. Nat. Prod. | pmid:2380715 |
| Alabaster O and Cassidy M | Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo. | 1978 | J. Natl. Cancer Inst. | pmid:625068 |
| Eagan RT et al. | Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication. | 1978 | J. Natl. Cancer Inst. | pmid:628025 |
| Schwarz LJ et al. | An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. | 2017 | J. Natl. Cancer Inst. | pmid:29059433 |
| Azvolinsky A | Conjugating antibodies to cytotoxic agents: getting the best of both worlds? | 2013 | J. Natl. Cancer Inst. | pmid:24244034 |
| Tuma RS | Enthusiasm for antibody-drug conjugates. | 2011 | J. Natl. Cancer Inst. | pmid:21972230 |
| Gupta RS | Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. | 1985 | J. Natl. Cancer Inst. | pmid:3855475 |
| Aldrich CD | Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine, and adriamycin. | 1979 | J. Natl. Cancer Inst. | pmid:224236 |
| Askoxylakis V et al. | Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. | 2016 | J. Natl. Cancer Inst. | pmid:26547932 |